Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. J of Skin [Internet]. 2024 Jul. 23 [cited 2025 Apr. 4];8(4):s404. Available from: https://skin.dermsquared.com/skin/article/view/2860